R R

What Is Ruconest?

Ruconest is a prescription biologic medication containing recombinant human C1 esterase inhibitor. It is approved to treat acute attacks of hereditary angioedema in adults and adolescents. Hereditary angioedema is a rare genetic disorder that causes recurrent swelling in areas such as the face, hands, feet, abdomen, and airways. Ruconest replaces the activity of a protein that helps regulate inflammatory pathways involved in swelling. It is supplied as a powder that is reconstituted for intravenous administration. Ruconest treats attacks after they begin rather than providing routine long-term prevention. It is produced using milk from genetically engineered rabbits, making rabbit allergy an important contraindication.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Ruconest?

Ruconest is a prescription biologic medication containing recombinant human C1 esterase inhibitor. It is approved to treat acute attacks of hereditary angioedema in adults and adolescents. Hereditary angioedema is a rare genetic disorder that causes recurrent swelling in areas such as the face, hands, feet, abdomen, and airways. Ruconest replaces the activity of a protein that helps regulate inflammatory pathways involved in swelling. It is supplied as a powder that is reconstituted for intravenous administration. Ruconest treats attacks after they begin rather than providing routine long-term prevention. It is produced using milk from genetically engineered rabbits, making rabbit allergy an important contraindication.

read more about ruconest ...

Copy this HTML:

Copy HTML Copied!

How Does Ruconest Work?

Ruconest replaces C1 esterase inhibitor activity that is deficient or dysfunctional in many patients with hereditary angioedema. C1 esterase inhibitor regulates several protein systems, including the contact, complement, and coagulation pathways. During hereditary angioedema attacks, uncontrolled contact system activity can increase bradykinin production. Bradykinin makes blood vessels more permeable, allowing fluid to accumulate in surrounding tissues and causing swelling. Recombinant C1 esterase inhibitor helps control this activity and reduce attack-related swelling. Ruconest does not repair the underlying genetic condition or eliminate the possibility of future attacks. Its purpose is to treat an acute episode.

What Condition Does Ruconest Treat?

Ruconest is approved for acute hereditary angioedema attacks in adults and adolescents. Hereditary angioedema can cause painful abdominal swelling, swelling of the extremities, or swelling involving the face and upper airways. Attacks may develop without warning and vary in severity. Ruconest is not indicated for routine prevention of attacks. Its effectiveness has not been established specifically in patients with laryngeal attacks, which can obstruct breathing and require emergency treatment. A clinician confirms the diagnosis and creates an individualized attack-management plan. Patients with suspected airway involvement require immediate medical evaluation, regardless of their prescribed treatment.

How Is Ruconest Administered?

Ruconest is administered by slow intravenous injection after the powder has been reconstituted. The recommended dose for patients weighing less than 84 kg is 50 units per kilogram of body weight. Patients weighing 84 kg or more receive 4,200 units. Each dose must not exceed 4,200 units and is generally administered over approximately five minutes. A second dose may be given if attack symptoms persist, but no more than two doses should be administered within 24 hours. Ruconest is supplied in single-use vials containing 2,100 units. Appropriately trained patients may administer treatment themselves after receiving instruction from a qualified healthcare professional.

What Are the Side Effects and Warnings of Ruconest?

Possible adverse effects include headache, nausea, and other treatment-related reactions. Serious hypersensitivity reactions, including anaphylaxis, can occur. Ruconest is contraindicated in patients with known or suspected allergies to rabbits or rabbit-derived products and in those with a history of immediate hypersensitivity to C1 esterase inhibitor preparations. Because it is derived from recombinant protein production involving rabbits, allergy history must be reviewed before treatment. Patients should be monitored for signs of an allergic reaction, including hives, difficulty breathing, or sudden changes in blood pressure. Hereditary angioedema attacks involving the throat remain medical emergencies because airway swelling can become life-threatening.

Common Questions About Ruconest

Is Ruconest used to prevent hereditary angioedema attacks?

No. Ruconest is approved to treat acute hereditary angioedema attacks after they begin, not for routine long-term prevention.

Can patients administer Ruconest at home?

Yes. Appropriately trained patients may self-administer Ruconest intravenously after receiving instruction from a qualified healthcare professional.

Why is rabbit allergy important with Ruconest?

Ruconest is produced using milk from genetically engineered rabbits. It is contraindicated in patients with known or suspected allergies to rabbits or rabbit-derived products.

Can Ruconest treat throat swelling?

Its effectiveness specifically for laryngeal hereditary angioedema attacks has not been established. Throat swelling requires emergency medical attention because breathing can become obstructed.

References

C1-Esterase Inhibitor (Recombinant) Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622015.html. Date Accessed November 4, 2026.

DailyMed - RUCONEST (C1 esterase inhibitor [recombinant]) injection, powder, for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66d3fecb-32a4-7781-e053-2a91aa0a83ca. Date Accessed November 4, 2026.

RUCONEST. U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/ruconest. Date Accessed November 4, 2026.

RUCONEST Patient Product Information. U.S. Food and Drug Administration. https://www.fda.gov/media/89212/download. Date Accessed November 4, 2026.

Ruconest Product Details. U.S. Food and Drug Administration Purple Book. https://purplebooksearch.fda.gov/index.cfm?blaNo=125495&event=productdetails. Date Accessed November 4, 2026.